Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

With Gland Pharma Limited's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 24.879885
debtToEquity 3.717000
earningsGrowth 0.066000
revenueGrowth -0.104000
grossMargins 0.553660
operatingMargins 0.190480
trailingEps 42.800000
forwardEps 65.010000

GLAND's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
Gland Pharma Limited's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
GLAND's negative gross and operating margins suggest that the company is experiencing losses at both the production and operational levels. This could point to inefficiencies or declining demand for its products.
Gland Pharma Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Gland Pharma Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for GLAND
Price projections for GLAND

Price projections for Gland Pharma Limited have been gradually lowered, signaling reduced optimism among analysts. This downward adjustment suggests that the company may face challenges in meeting previous growth expectations.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


15 sell transactions of GLAND were recorded, with market price hovering near 1815.1299967447917.There were no sell transactions throughout the period under consideration.The higher volume of buys compared to sells near current Gland Pharma Limited price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


Analysts have developed a sell bias for Gland Pharma Limited, urging caution for investors. It's essential to base investment decisions on multiple market indicators to avoid hasty conclusions. Relying on a broader scope of information will provide a more accurate assessment of Gland Pharma Limited's overall potential.